Cannabis Strains and Effects: Understanding Cannabinoids and Terpenes

Dr. Sheridan Walter
Dr. Jennie Stanford
Written by Dr. Sheridan Walter on 04 June 2025
Medically reviewed by Dr. Jennie Stanford on 04 June 2025

Comparing the plant types of Cannabis indica, sativa, or hybrid gives a rough idea of cannabis effects, but the true drivers are cannabinoids (like THC and CBD) and terpenes (like myrcene and limonene). This overview explains how strain categories, chemovars, cannabinoids, and terpenes shape the cannabis experience, how they interact (the entourage effect), and how to match substance profiles to specific needs, while noting their benefits, risks, and harm-reduction strategies.

Key takeaways:
  • Strain labels are a shorthand. Genetics and lab tests (detecting cannabinoids  and  terpenes) predict effects far better than Cannabis indica vs. Cannabis sativa alone.
  • Chemistry matters. THC delivers euphoria and appetite stimulation; CBD eases anxiety and inflammation; and terpenes fine-tune mood, energy, and body sensations.
  • Match profiles to goals. For example, myrcene- and CBN-rich Cannabis indica can be used to improve sleep; limonene and pinene in Cannabis sativa help with focus; and balanced CBD:THC with linalool may provide anxiety relief.
a photo of a shelf with four transparent jars filled with different cannabis strains

Cannabis strains: Indica vs. Sativa vs. Hybrid

Traditionally, Cannabis indica and Cannabis sativa are regarded as two plant subspecies with different origins and traits. C. indica originated in the Hindu Kush region (within the Middle East, including the countries of Afghanistan, Pakistan, Tibet) and generally has a higher CBD content than C. sativa, with CBD:THC ratios near 1:1.

  1. indica strains are mostly described as producing a relaxing, systemic high that can help relieve pain, insomnia, and stress. In contrast, C. sativa comes from equatorial regions (as in Central America, South America, and Southeast Asia) and is perceived as more energizing and cerebral.
  2. sativa plants tend to contain more THC than CBD and are associated with alertness, creativity, and mood elevation (potentially aiding depression or appetite).
  3. hybrid plants are bred by cross-pollinating C. sativa and C. indica, resulting in a mix of traits. They can be C. indica-dominant, C. sativa-dominant, or balanced, offering tailored effects.

The table below summarizes these general differences. C. indica varieties are shown as “relaxing/soothing,” used for pain and sleep; C. sativa varieties are “energizing/uplifting,” used for fatigue or depression; and C. hybrid varieties vary by genetics.

General comparison of Cannabis sativa, Cannabis indica, and Cannabis hybrid varieties

StrainOriginAppearanceTHC:CBDEffectsCommon usesExample strains
SativaCentral/South America, Southeast  Asia Tall (up to 20 ft), narrow fan leaves Typically higher THC, low CBD (e.g., 18–25 % THC; < 1 % CBD) Uplifting, cerebral, energetic—helpful for fatigue, creativity Daytime use, depression, ADHD, creativity (popular claims) Jack Herer, Super Lemon Haze
IndicaHindu Kush region (Afghanistan, Pakistan, Tibet) Short (2–4 ft), broad fan leaves Often more balanced or higher CBD (e.g., 10–18 % THC; 1–4 % CBD) Relaxing, sedative, body-heavy—helpful for pain, insomnia Evening use, chronic pain, muscle tension, sleep (based on user reports) Granddaddy Purple, Northern Lights
HybridCrosses between C. sativa & C. indica Variable—depends on parental lineage Any ratio, tailored by plant genetics Combine or balance effects; actual effects depend on chemovar, not label Tailored per strain—e.g., 1:1 THC: CBD for balanced relief Blue Dream, Girl Scout Cookies

Note: Strain labels like "indica" or "sativa" are widely used in commerce, but genomic and chemotype research shows that these labels often do not align with cannabinoid or terpene content. Always consult lab-tested profiles over marketing claims.

Chemovars: Beyond strain selection

Rather than relying solely on plant appearance or name, the chemovar (chemical variety) system classifies cannabis by its dominant cannabinoids. A standard scheme categorizes plants into these groups:

  • Type I (THC-dominant): High Δ9-THC, minimal CBD (<0.5%). These are the classic psychoactive marijuana strains (recreational focus).
  • Type II (Balanced): Roughly equal THC and CBD (~1:1). These “intermediate” varieties can provide moderate psychoactivity with substantial therapeutic CBD (often used for pain/anxiety relief with less intoxication).
  • Type III (CBD-dominant): Low THC (<0.3%), high CBD. These are hemp-like strains used for medical hemp products (anti-inflammatory, anti-anxiety benefits without intoxication).
  • Type IV (CBG-dominant): (Less common) High cannabigerol (CBG), with low THC/CBD. CBG is the precursor to THC/CBD in the plant; plants high in CBG may have unique neuroprotective or appetite-stimulating effects.

The table below illustrates these chemovar types.

Chemovar typeDominant cannabinoid ratioPsychoactivityTypical uses
Type ITHC ≫ CBD (e.g., > 15 % THC; < 0.5 % CBD) Strong psychoactive (“high”) Pain relief, appetite stimulation, recreation
Type IITHC ≈ CBD (≈ 1:1) Moderate psychoactivity Anxiety relief, neuropathic pain
Type IIICBD ≫ THC (e.g., > 10 % CBD; < 0.3 % THC) Minimal psychoactivity Epilepsy, inflammation, anxiety without intoxication
Type IVCBG ≫ THC/CBD Non-intoxicating Experimental: anti-inflammatory, neuroprotection

Why chemovars? They align with regulatory definitions (e.g., hemp vs. marijuana) and guide dosing more reliably than botanical.

Cannabinoids: The building blocks of cannabis effects

Cannabinoids interact with the body’s endocannabinoid system to yield varied effects:

Terpenes: The aromatic modulators

Terpenes contribute aroma and modulate cannabinoid effects via pharmacological actions and receptor interactions.

TerpeneAromaPotential effectsSynergy with cannabinoids
MyrceneEarthy, cloveSedation, muscle relaxation, anti-inflammatoryEnhances THC’s sedative “couch-lock”
LimoneneCitrusUplifted mood, anti-anxietyMay blunt THC-induced anxiety
LinaloolFloral, lavenderCalming, analgesicAugments CBD’s anxiolytic/sedative effects
α/β-PinenePineAlertness, bronchodilation, and memory supportCounters THC memory impairment
β-CaryophylleneSpicy, pepperAnti-inflammatory via CB₂ activationBolsters CBD’s anti-inflammatory action

The entourage effect: How cannabinoids and terpenes interact

The entourage effect refers to how cannabis compounds interact synergistically, meaning that whole-plant use may produce effects distinct from isolated cannabinoids. Specific cannabinoid–terpene combinations have been observed to produce enhanced or modulated effects. For example, adding limonene to THC can significantly reduce THC’s anxiety and paranoia, making the high feel smoother.

Similarly, pinene can sharpen a THC high and help mitigate short-term memory loss and panic. Myrcene tends to enhance sedation and analgesia when paired with THC. Combinations like THC and linalool can make the experience more relaxing and sleep-inducing; conversely, high THC with low terpenes may feel harsher.

The table below lists some common pairings and their reported synergistic effects.

Combination (Cannabinoid + terpene)Reported effect
THC + limoneneSmoother, less anxiety-prone high
THC + pineneEnhanced focus; reduced short-term memory lapses
THC + myrceneDeeper muscle relaxation and sedation
CBD + β-caryophylleneStronger anti-inflammatory synergy via CB₂
THC + linaloolIncreased calm and sleepiness

Matching combinations to aid needs

Guidance for medical or wellness use—adjust based on personal response:

  1. Sleep/insomnia: Choose a C. indica-leaning chemovar (Type I or hybrid) that is high in myrcene (> 0.5 %) and CBN (2–5 mg), with moderate levels of THC (10–15 %).
  2. Anxiety/stress: Start with balanced THC:CBD (1:1) plus limonene and linalool. Avoid pure THC products.
  3. Pain management: Use Type I or II chemovars with THC ≥ 10 mg and CBD ≥ 10 mg, plus anti-inflammatory terpenes (caryophyllene, myrcene).
  4. Appetite stimulation: Consider high-THC chemovars (Type I) with added CBG to boost hunger; avoid THCV-rich products.
  5. Focus/energy: Opt for C. sativa-dominant profiles with pinene and limonene—microdose THC (≤ 5 mg) for clarity.

Always start low and go slow, track the dose and its effects, and adjust accordingly.

Making informed choices about cannabis

Benefits:

  • THC is FDA-approved for chemotherapy nausea and HIV cachexia.
  • CBD (Epidiolex) treats epilepsy.
  • Growing evidence supports cannabis for chronic pain and spasticity.

Risks:

Cannabis addiction and harm reduction

While cannabis carries a lower risk of fatal overdose than opioids or alcohol, it can lead to cannabis use disorder, cognitive impairment, and psychiatric exacerbation, especially with frequent high-THC use and early initiation. A harm reduction approach acknowledges that not all users seek abstinence and offers pragmatic strategies to reduce harm while respecting user autonomy.

Core harm reduction strategies

  • Set daily intake limits and track patterns. Use sessions should be intentional, not automatic. Frequent, daily, or “wake and bake” use is strongly linked to dependency and reduced motivation. Use journals or digital trackers to monitor frequency and dosage.
  • Schedule regular tolerance breaks. CB1 receptor downregulation from chronic THC exposure reduces the effect and drives escalating use. Short 48–72 hour breaks can restore sensitivity and help users reassess dependence risk without requiring complete abstinence.
  • Avoid operating vehicles or machinery while impaired. Cannabis significantly impairs motor coordination, reaction time, and attention, even when users feel “sober.” Driving within six hours of use (or longer for edibles) increases the risk of a crash.
  • Do not combine with alcohol or other depressants. THC and alcohol together multiply cognitive and physical impairment. Alcohol also increases THC absorption, intensifying the effects and increasing the risk of nausea, blackouts, or panic reactions.
  • Use regulated, lab-tested cannabis products. Illicit cannabis may contain mold, pesticides, or synthetic cannabinoids. Always check for Certificates of Analysis (COAs) when possible.
  • Select products based on effect, not intensity. Avoid THC concentrations >20% or potent concentrates, like dabs and wax, which have higher addiction potential. Products with balanced THC:CBD ratios are associated with fewer psychotic-like symptoms and anxiety.
  • Start low, go slow—especially with edibles. Edibles have a delayed onset (30–120 mins) and longer duration (4–8 hours). Novice users often redose too early, leading to intense discomfort or panic. Always wait before consuming more.
  • Delay initiation and avoid adolescent use. Early onset (before age 18) is linked to higher rates of cannabis use disorder, lower educational outcomes, and increased risk for psychosis in vulnerable populations.
  • Use contextually—avoid habitual pairing with other activities. Avoid linking cannabis to daily tasks, like eating, gaming, or unwinding, unless this is intentional. Anchoring cannabis to specific contexts can prevent habitual, unthinking use.
  • Be alert to signs of withdrawal or emotional dependency. Irritability, insomnia, appetite changes, and mood swings during breaks may signal early withdrawal. Support through sleep hygiene, light exercise, and structured routines is essential.

Respecting cannabis means respecting the person using it—by offering facts, not fear, and strategies, not shame.

Was this page helpful?

Your feedback allows us to continually improve our information

Resources:

  1. Dresden, D. (2024, January 26). Indica vs. sativa: What’s the difference? Medical News Today. Retrieved from
  2. Small, E., & Cronquist, A. (1976). A practical and natural taxonomy for Cannabis. Taxon, 25(4), 405–435.
  3. Piomelli, D., & Russo, E. B. (2016). The Cannabis sativa versus Cannabis indica debate: An interview with Ethan Russo, MD. Cannabis and Cannabinoid Research, 1(1), 44–46.
  4. Hazekamp, A., Tejkalová, K., & Papadimitriou, S. (2016). Cannabis: From cultivar to chemovar II—A metabolomics approach to cannabis classification. Cannabis and Cannabinoid Research, 1(1), 202–215.
  5. ElSohly, M. A., & Slade, D. (2005). Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sciences, 78(5), 539–548.
  6. Vergara, D., White, K. H., Keepers, K. G., Kane, N. C. (2021). Widely assumed phenotypic associations in Cannabis sativa lack a shared genetic basis. PeerJ, 9, e10672.
  7. Gülck, T., & Møller, B. L. (2020). Phytocannabinoids: Origins and biosynthesis. Trends in Plant Science, 25(10), 985–1004.
  8. Hoch, E., Volkow, N. D., Friemel, C. M., Lorenzetti, V., Freeman, T. P., & Hall, W. (2025). Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits. European archives of psychiatry and clinical neuroscience, 275(2), 281–292.
  9. DrugBank. (n.d.). Dronabinol. DrugBank Online. Retrieved May 7, 2025, from
  10. Britch, S. C., Babalonis, S., & Walsh, S. L. (2020). Cannabidiol: Pharmacology and Therapeutic Targets. Psychopharmacology, 238(1), 9.
  11. Russo E. B. (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British journal of pharmacology, 163(7), 1344–1364.
  12. Hashim, I. A. (2024). Therapeutic drugs and toxicology testing. Tutorials in Clinical Chemistry, 375–418.
  13. Abioye, A., Ayodele, O., Marinkovic, A., Patidar, R., Akinwekomi, A., & Sanyaolu, A. (2020). Δ9-Tetrahydrocannabivarin (THCV): A commentary on potential therapeutic benefits for the management of obesity and diabetes. Journal of Cannabis Research, 2, 6.
  14. Song, Y., Seo, S., Lamichhane, S., Seo, J., Hong, J. T., Cha, H. J., & Yun, J. (2021). Limonene has anti-anxiety activity via adenosine A2A receptor-mediated regulation of dopaminergic and GABAergic neuronal function in the striatum. Phytomedicine: international journal of phytotherapy and phytopharmacology, 83, 153474.
  15. S Maia, J. G., Fontes-Júnior, E. A., & Maia, S. F. (2022). Linalool as a Therapeutic and Medicinal Tool in Depression Treatment: A Review. Current Neuropharmacology, 20(6), 1073.
  16. Salehi, B., Upadhyay, S., Orhan, I. E., Jugran, A. K., Jayaweera, S. L., Dias, D. A., Sharopov, F., Taheri, Y., Martins, N., Baghalpour, N., Cho, W. C., & Sharifi-Rad, J. (2019). Therapeutic Potential of α- and β-Pinene: A Miracle Gift of Nature. Biomolecules, 9(11), 738.
  17. Jha, N. K., Sharma, C., Hashiesh, H. M., Arunachalam, S., Meeran, M. N., Javed, H., Patil, C. R., Goyal, S. N., & Ojha, S. (2021). β-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19. Frontiers in Pharmacology, 12, 590201.
  18. Johns Hopkins Medicine. (2024, April 10). Researchers show chemical found naturally in cannabis may reduce anxiety-inducing effects of THC. Retrieved from
  19. Robbins, C. (2019, January 28). Pinene: The anti-inflammatory terpene that helps respiratory conditions. Cannabis Aficionado. Retrieved from
  20. ARCannabisClinic. (2024, November 14). What are high pinene strains? Retrieved from
  21. Surendran, S., Qassadi, F., Surendran, G., Lilley, D., & Heinrich, M. (2021). Myrcene—What Are the Potential Health Benefits of This Flavouring and Aroma Agent? Frontiers in Nutrition, 8, 699666.
  22. Benamar, K. (2024). IUPHAR review- Preclinical models of neuropathic pain: Evaluating multifunctional properties of natural cannabinoid receptors ligands. Pharmacological Research, 199, 107013.
  23. Weston-Green, K., Clunas, H., & Naranjo, C. J. (2021). A Review of the Potential Use of Pinene and Linalool as Terpene-Based Medicines for Brain Health: Discovering Novel Therapeutics in the Flavours and Fragrances of Cannabis. Frontiers in Psychiatry, 12, 583211.
  24. Acerno, A. (2022, February 9). Why does the 1:1 CBD to THC ratio work so well? Leafwell. Retrieved from
  25. Francomano, F., Caruso, A., Barbarossa, A., Fazio, A., La Torre, C., Ceramella, J., Mallamaci, R., Saturnino, C., Iacopetta, D., & Sinicropi, M. S. (2019). β-Caryophyllene: A Sesquiterpene with Countless Biological Properties. Applied Sciences, 9(24), 5420.
  26. Calapai, F., Cardia, L., Esposito, E., Ammendolia, I., Mondello, C., Lo Giudice, R., Gangemi, S., Calapai, G., & Mannucci, C. (2022). Pharmacological Aspects and Biological Effects of Cannabigerol and Its Synthetic Derivatives. Evidence-based complementary and alternative medicine: eCAM, 2022, 3336516.
  27. Bajtel, Á., Kiss, T., Tóth, B., Kiss, S., Hegyi, P., Vörhendi, N., Csupor-Löffler, B., Gede, N., Hohmann, J., & Csupor, D. (2022). The Safety of Dronabinol and Nabilone: A Systematic Review and Meta-Analysis of Clinical Trials. Pharmaceuticals (Basel, Switzerland), 15(1), 100.
  28. U.S. Food and Drug Administration. (2023). FDA and cannabis: Research and drug approval process.
  29. Hasin, D. S., Saha, T. D., Kerridge, B. T., Goldstein, R. B., Chou, S. P., Zhang, H., Jung, J., Pickering, R. P., Ruan, W. J., Smith, S. M., Huang, B., & Grant, B. F. (2015). Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry, 72(12), 1235–1242.
  30. Leung, J., Chan, G. C. K., Hides, L., & Hall, W. D. (2020). What is the prevalence and risk of cannabis use disorders among people who use cannabis? A systematic review and meta-analysis. Addictive Behaviors, 109, 106479.
  31. Colizzi, M., Iyegbe, C., Powell, J., Ursini, G., Porcelli, A., Bonvino, A., Taurisano, P., Romano, R., Masellis, R., Blasi, G., Morgan, C., Aitchison, K., Mondelli, V., Luzi, S., Kolliakou, A., David, A., Murray, R. M., Bertolino, A., & Forti, M. D. (2015). Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophrenia Bulletin, 41(5), 1171.
  32. Stone, B. M., & Sherman, B. J. (2023). Is it time for a cannabis harm reduction approach? Commentary on Sherman et al. (2022) and Borodovsky et al. (2022). Psychology of Addictive Behaviors, 37(5), 709–712.
  33. Swift, W., Copeland, J., & Lenton, S. (2000). Cannabis and harm reduction. Drug and Alcohol Review, 19(1), 101–112.
  34. Hall, W., & Degenhardt, L. (2014). Harm reduction policies for cannabis. In R. Pertwee (Ed.), Handbook of cannabis. Oxford University Press. Retrieved from
  35. Mok, J., Milloy, M.-J., Grant, C., Lake, S., DeBeck, K., Hayashi, K., Kerr, T., & Socías, M. E. (2023). Use of cannabis as a harm reduction strategy among people who use drugs: A cohort study. Cannabis and Cannabinoid Research, 8(4), 670–678.
  36. Ghelani, A. (2024). Perspectives on cannabis risks and harm reduction among youth in Early Psychosis Intervention programs: A qualitative study. Mental Health and Social Inclusion, 28(5), 668–677.
  37. Kruger, J. S., Kruger, D. J., & Collins, R. L. (2020). Knowledge and practice of harm reduction strategies among people who report frequent cannabis use. Health Promotion Practice, 22(1), 24–30.
  38. Siklos-Whillans, J., Bacchus, A., & Manwell, L. A. (2020). A scoping review of the use of cannabis and its extracts as potential harm reduction strategies: Insights from preclinical and clinical research. International Journal of Mental Health and Addiction, 19(5), 1527–1550.

Activity History - Last updated: 04 June 2025, Published date:


Reviewer

Dr. Jennie Stanford

MD, FAAFP, DipABOM

Jennie Stanford, MD, FAAFP, DipABOM is a dual board-certified physician in both family medicine and obesity medicine. She has a wide range of clinical experiences, ranging from years of traditional clinic practice to hospitalist care to performing peer quality review to ensure optimal patient care.

Activity History - Medically Reviewed on 03 June 2025 and last checked on 04 June 2025

Medically reviewed by
Dr. Jennie Stanford

Dr. Jennie Stanford

MD, FAAFP, DipABOM

Reviewer

Recovered Branding BG
Ready to talk about treatment? Call today. (833) 787-9718
Helpline Information

Calls to numbers marked with (I) symbols will be answered or returned by one of the treatment providers listed in our Terms and Conditions, each of which is a paid advertiser.

In calling the helpline you agree to our Terms and Conditions. We do not receive any fee or commission dependent upon which treatment or provider a caller chooses.

There is no obligation to enter treatment.

Access State-Specific Provider Directories for detailed information on locating licensed service providers and recovery residences in your area.

For any specific questions please email us at info@recovered.org

Related guides